1. Home
  2. GMM vs XLO Comparison

GMM vs XLO Comparison

Compare GMM & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Mofy Metaverse Limited

GMM

Global Mofy Metaverse Limited

HOLD

Current Price

$1.38

Market Cap

39.6M

Sector

N/A

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$0.73

Market Cap

41.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GMM
XLO
Founded
2017
2016
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.6M
41.8M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
GMM
XLO
Price
$1.38
$0.73
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$2.00
AVG Volume (30 Days)
40.6K
419.8K
Earning Date
08-18-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.79
N/A
Revenue
$48,171,048.00
$31,804,000.00
Revenue This Year
N/A
$626.78
Revenue Next Year
N/A
$79.08
P/E Ratio
$0.81
N/A
Revenue Growth
41.74
588.40
52 Week Low
$0.94
$0.62
52 Week High
$4.75
$1.70

Technical Indicators

Market Signals
Indicator
GMM
XLO
Relative Strength Index (RSI) 54.16 60.50
Support Level $0.94 $0.63
Resistance Level $1.54 $0.68
Average True Range (ATR) 0.12 0.03
MACD 0.04 0.01
Stochastic Oscillator 75.78 87.72

Price Performance

Historical Comparison
GMM
XLO

About GMM Global Mofy Metaverse Limited

Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Share on Social Networks: